U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Echo Therapeutics, Inc. (ECTE)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.04050.0000 (0.0000%)
At close: 10:24AM EDT
People also watch
BGMDNNVCNAVBEDAPBSPM

Echo Therapeutics, Inc.

99 Wood Avenue South
Suite 302
Iselin, NJ 08830
United States
732-201-4189
http://www.echotx.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees19

Key Executives

NameTitlePayExercisedAge
Mr. Alan W. Schoenbart CPAChief Exec. Officer, Chief Financial Officer and Director260kN/A58
Ms. Christine H. OlimpioDirector of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

Corporate Governance

Echo Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.